In vitro effect of thymosin-α1 and interferon-α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C

被引:36
作者
Andreone, P
Cursaro, C
Gramenzi, A
Margotti, M
Ferri, E
Talarico, S
Biselli, M
Felline, F
Tuthill, C
Martins, E
Gasbarrini, G
Bernardi, M
机构
[1] Univ Bologna, Policlin S Orsola, Dipartimento Med Interna Cardioangiol & Epatol, I-40138 Bologna, Italy
[2] SciClone Pharmacuet Inc, San Mateo, CA USA
[3] Univ Cattolica Sacro Cuore, Med Clin, Rome, Italy
关键词
cytokines; hepatitis C; immune response; interferon-alpha; Th1; thymosin-alpha; 1;
D O I
10.1046/j.1365-2893.2001.00285.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Current evidence suggests that increased expression of Th1-associated cytokines is important for immune-mediated eradication of hepatitis C infection, while an increase in Th2-associated cytokines is associated with persistence of infection. In this study we evaluated the effects of thymosin-alpha1 (TA1), a naturally occurring thymic peptide, and interferon-alpha (IFN-alpha) on cytokine production in peripheral blood mononuclear cells from untreated patients with chronic hepatitis C. We examined the effect of incubation with TA1, IFN-alpha, or both, on production of Th1-associated cytokines (IL-2, IFN-gamma), Th2-associated cytokines (IL-4, IL-10), and synthesis of the antiviral protein 2',5'-oligoadenylate synthetase. TA1 treatment induced a significant increase in production of IL-2 and 2',5'-oligoadenylate synthetase. Smaller increases were also seen after treatment with IFN-alpha, while incubation with TA1 and IFN-alpha together led to an additive or synergistic effect. Incubation with TA1 resulted in a decrease in IL-4 and IL-10, whereas IFN-alpha increased these cytokines. The addition of TA1 to IFN-alpha significantly reversed this IFN-alpha -induced increase. Hence, TA1 treatment could benefit patients with hepatitis C infection by increasing the Th1-type response, fundamental for sustained clearance of hepatitis C; and by decreasing the Th2-type response, associated with persistence of viraemia.
引用
收藏
页码:194 / 201
页数:8
相关论文
共 46 条
[31]  
MUTCHNICK MG, 1991, HEPATOLOGY, V14, P409, DOI 10.1016/0270-9139(91)90176-V
[32]   Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Gretch, DR ;
Wiley, TE ;
Layden, TJ ;
Perelson, AS .
SCIENCE, 1998, 282 (5386) :103-107
[33]  
OATES KK, 1995, BIOL THERAPY CANC, P841
[34]   Treatment of chronic hepatitis C in special groups [J].
Pol, S ;
Zylberberg, H ;
Fontaine, H ;
Bréchot, C .
JOURNAL OF HEPATOLOGY, 1999, 31 :205-209
[35]   Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus [J].
Poynard, T ;
Marcellin, P ;
Lee, SS ;
Niederau, C ;
Minuk, GS ;
Ideo, G ;
Bain, V ;
Heathcote, J ;
Zeuzem, S ;
Trepo, C ;
Albrecht, J .
LANCET, 1998, 352 (9138) :1426-1432
[36]   Combination thymosin alpha(1) and lymphoblastoid interferon treatment in chronic hepatitis C [J].
Rasi, G ;
DiVirgilio, D ;
Mutchnick, MG ;
Colella, F ;
SinibaldiVallebona, P ;
Pierimarchi, P ;
Valli, B ;
Garaci, E .
GUT, 1996, 39 (05) :679-683
[37]   Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B [J].
Rasi, G ;
Mutchnick, MG ;
DiVirgilio, D ;
SinibaldiVallebona, P ;
Pierimarchi, P ;
Colella, F ;
Favalli, C ;
Garaci, E .
JOURNAL OF VIRAL HEPATITIS, 1996, 3 (04) :191-196
[38]  
REISER M, 1995, GASTROENTEROLOGY, V108, pA1154
[39]  
Salvati F, 1996, ANTICANCER RES, V16, P1001
[40]  
SERRATE SA, 1987, J IMMUNOL, V139, P2338